ABSTRACT
The purpose of this study was to assess whether there is an improvement in motor function in persons with cerebral palsy (CP) who have had a reduction of muscle tone by continuous intrathecal baclofen infusion. This was a prospective, open label, non-blinded case series without a control group, conducted at multiple centres. There were 31 subjects, aged 4-29 years. All had a pre-treatment mean lower extremity Ashworth scores of >or= 3 and a significant reduction in tone after a bolus injection of intrathecal baclofen (ITB) and received an implanted pump for continuous delivery of ITB. Motor function was assessed by the Gross Motor Function Measure (GMFM) prior to and 1 year following pump implantation. Significant improvement (p < 0.05) in mean GMFM scores was seen in subjects < 8 years (mean change 4.1) and in those from 8-18 years (mean change 3.7) and in subjects with CP Classes 2 and 5 (mean changes 6.2 and 2.9). There was a statistically significant decrease (p < 0.05) in Ashworth scores in CP classes 2-5. Subjects or their caregivers that completed a survey about perceived changes stated that motor control, positioning and endurance improved.
Subject(s)
Baclofen/therapeutic use , Cerebral Palsy/prevention & control , Motor Activity/drug effects , Muscle Relaxants, Central/therapeutic use , Adolescent , Adult , Baclofen/administration & dosage , Cerebral Palsy/physiopathology , Child , Child, Preschool , Follow-Up Studies , Humans , Infusion Pumps, Implantable , Injections, Spinal , Lower Extremity/physiopathology , Motor Activity/physiology , Muscle Contraction/drug effects , Muscle Contraction/physiology , Muscle Relaxants, Central/administration & dosage , Muscle Spasticity/physiopathology , Muscle Spasticity/prevention & control , Patient Satisfaction , Physical Endurance/physiology , Posture/physiology , Prospective StudiesABSTRACT
The purpose of this study was to assess whether reduction of muscle tone by continuous intrathecal baclofen infusion affects the progression of hip subluxation in persons with cerebral palsy. This prospective, open-label, case series was conducted at multiple specialty referral centers. There were 33 subjects, ages 4 to 31 years. All had a pretreatment lower extremity Ashworth score of >/=3; all subjects had a significant reduction in tone after a bolus injection of intrathecal baclofen and received an implanted pump for continuous delivery of intrathecal baclofen. Subjects had hip x-rays before and 1 year after pump implantation. The primary outcome measure was change in absolute hip migration percentage. One third of the hips had an increase of absolute migration percentage of 5% or more; 12% of the hips had a decrease of migration percentage of 5% or more. Change of migration percentage class was used as a second outcome criterion. 90.9% of hips manifested no deterioration or had improvement of their migration percentage class during the year of intrathecal baclofen therapy. The observed changes were not associated with the subject's age or the severity of cerebral palsy.
Subject(s)
Baclofen/administration & dosage , Cerebral Palsy/drug therapy , Hip Dislocation, Congenital/drug therapy , Muscle Relaxants, Central/administration & dosage , Adolescent , Adult , Cerebral Palsy/classification , Child , Child, Preschool , Female , Follow-Up Studies , Hip Dislocation, Congenital/classification , Humans , Infusion Pumps, Implantable , Injections, Spinal , Locomotion/drug effects , Male , Muscle Tonus/drug effects , Prospective Studies , Treatment OutcomeABSTRACT
We describe a dramatic case of an identical twin presenting at birth with unilateral congenital glaucoma. Because of the suspicion of neurofibromatosis 1 a magnetic resonance image of the neural axis was obtained, which revealed a plexiform neurofibroma with spinal cord impingement. Diagnosis of neurofibromatosis 1 was confirmed by 3 months of age with the emergence of café-au-lait spots. This case was compared with all 19 reports published in the English literature of neurofibromatosis 1 associated with congenital glaucoma. Initial presentation, family history, characteristics ofthe clinical syndrome, and outcome of glaucoma in infants with neurofibromatosis 1 and congenital glaucoma were reviewed. A plexiform neurofibroma of the ipsilateral eyelid was present in eight patients and ipsilateral facial hypertrophy occurred in three patients. Café-au-lait spots appeared between the ages of 5 weeks and 8 years; none of the patients were reported to have café-au-lait spots at birth. Newborns with unilateral congenital glaucoma should raise high suspicion for neurofibromatosis 1 and its associated findings, which might need immediate intervention.
Subject(s)
Glaucoma/congenital , Infant, Premature , Neurofibroma, Plexiform/etiology , Neurofibroma, Plexiform/pathology , Neurofibromatosis 1/complications , Cafe-au-Lait Spots/etiology , Female , Glaucoma/genetics , Glaucoma/pathology , Humans , Infant, Newborn , Magnetic Resonance Imaging , Neurofibroma, Plexiform/genetics , Neurofibromatosis 1/diagnosis , Neurofibromatosis 1/genetics , Twins, MonozygoticABSTRACT
In treating patients with hydrocephalus, cerebral ventricular shunts and their complications are often encountered by the primary care provider. Caring for these patients can provoke anxiety and doubt in those who have had little exposure in dealing with shunts. Becoming familiar with the clinical findings, etiology, and treatment of hydrocephalus, as well as the signs and symptoms of cerebral ventricular shunt complications, will aid the primary care physician in the management, treatment, referral, and continuing care of these patients.
